MEI Lab
Medical & Health Informatics Laboratories
Cardiovascular Bio Digital Twin
NTT Research’s MEI Lab is on the forefront of medicine with its digital twin technology. Specifically, its focus on creating the Cardiovascular Bio Digital Twin reflects a need to better treat ischemic heart disease, which is the world’s leading cause of death. The MEI Lab’s Bio Digital Twin technology has the ability to revolutionize and individualize its treatment with precision cardiology.
One such revolution is the Autonomous Closed-Loop Intervention System, or ACIS. Developed in cooperation with Japan’s National Cerebral and Cardiovascular Center (NCVC), the ACIS is a groundbreaking technology for the treatment of acute myocardial infarction. Based on the idea that if enough is known about a patient to create a digital representation of their physiology, the ACIS could then use that information to administer treatment faster and more efficiently.
Presently, three classes of medications must be adjusted individually by physicians. It’s a precise, time-consuming process where every passing second represents the loss of healthy heart tissue. Because of how it learns from the patient, the ACIS can adjust those medications simultaneously, saving both time and muscle.
It also works in tandem with medical mechanical assistance devices, and is flexible enough to accommodate new drugs and treatments. Ultimately, the ACIS gives patients the best chance of recovery and unburdens physicians. In addition to superior outcomes, the ACIS is automated and designed to be deployed almost anywhere in the world to render care in even the most underserved communities.
Introducing ACIS
Members of the MEI Lab and NCVC explain how the Autonomous Closed-Loop Intervention System (ACIS) will allow physicians to treat acute heart attack and acute heart failure patients more quickly and effectively.